Compare Huntington Bancshares Incorporated (HBAN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Regeneron Pharmaceuticals Inc — how do they compare? Huntington Bancshares Incorporated trades at $17.88 (market cap $35.93B), while Regeneron Pharmaceuticals Inc trades at $799.36 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.3× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| HBAN | REGN | |
|---|---|---|
Market Cap | $35.93B | $82.06B |
Sector | Financials | Health |
52-Week High | $19.27 | $812.27 |
52-Week Low | $15.02 | $555.51 |
Dividend Yield | 3.49% | 0.47% |
Enterprise Value | — | $76.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $17.82, up 1.25% recently, with a bullish technical outlook and mixed earnings history. The company reported Q2 2026 EPS of $0.33, missing estimates, but revenue growth to $8.13B in 2025 supports a net income margin of 24.77%. Analysts maintain a consensus price target of $19.78, with 45% recommending Buy, amid concerns over rising deposit costs noted in recent news.
HBAN offers potential upside with a reasonable P/E of 13.68 and dividend yield, but faces risks from expense pressures and competitive banking dynamics. The stock's outlook hinges on execution of its ROTCE target of 18-19% by 2027, balancing growth opportunities with macroeconomic headwinds.
Regeneron Pharmaceuticals (REGN) trades at $794.71, down 1.65% on the day, with strong fundamentals including a P/E of 19.72 and net income margin of 27.86%. The stock is in a bullish technical trend, supported by moving averages, though RSI levels indicate overbought conditions. Recent quarterly EPS results have consistently beaten expectations, and the company maintains robust cash flow from operations of $4.98 billion in 2025. However, multiple class action lawsuits related to clinical trial disclosures present a near-term headwind.
The outlook remains positive due to earnings strength and analyst consensus, but legal risks and high valuation multiples warrant caution. Upside is supported by product growth in Eylea HD and Dupixent, while downside risks include litigation outcomes and potential regulatory scrutiny. The stock trades above the consensus price target of $756.93, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
